Sweden · Delayed Price · Currency is SEK Acarix AB Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw 26% revenue growth, led by 87% U.S. market expansion and 64% increase in CADScor deliveries. Operating costs fell 23%, net loss improved 27%, and patch sales rose 73%. New payer and MDR certification support further global growth.
-
Q3 saw 137% global revenue growth, 95% increase in system deployments, and 49% reduction in net loss, driven by MENA expansion and robust U.S. performance. Gross margin remained strong at 85%, with expanding reimbursement and new clinical milestones.
-
Q2 saw strong U.S. growth with a 27% increase in system deliveries and 53% patch sales growth in H1, while gross margin rose to 94% and operating costs fell 24%. Revenue declined due to European divestment, but new global distribution and reimbursement wins position the company for future profitability.
-
Q1 2025 saw robust U.S. growth with system deliveries up 46% and patch sales up 104%, while global revenue rose 11%. Gross margin dipped due to a strategic sale, but patch margins remained strong. Key partnerships and clinical trials are advancing, with reimbursement progress ongoing.
Fiscal Year 2024
-
Q4 2024 delivered 333% growth in systems installed, 88% patch revenue growth, and a 27% OpEx reduction, driven by a new subscription model and expanded U.S. market access. Achievements include a new CMS reimbursement code, key hires, and a SEK 87M capital raise, supporting a path to profitability by Q2 2026.
-
Q3 saw strong U.S. growth with 116% more patches sold and 89% higher patch sales, driven by new verticals and a key CMS reimbursement win. Gross margin rose to 90%, OpEx fell 12%, and a new clinical trial is set to support further expansion.
-
Q2 saw record revenue and gross profit growth, driven by a new commercial model and strong US patch sales. Awaiting key CMS reimbursement decisions and private payer agreements, with significant market expansion and improved financials positioning for future growth.